Peptide Vaccines for Cancer

REFERENCES

• Townsend A.R.M., Gotch R.M., Davey J. Cytotoxic Cells Recognize Fragments of the Influenza Nucleoprotein. Cell 1985; 42: 457–467
   PubMed Web of Science ®Google Scholar
• Townsend A.R.M., Rothbard J., Gotch F.M., Bahadur G., Wraith P., McNechael A.J. The Epitopes of Influenza Nucleoprotein Recognized by Cytotoxic T Lymphocytes can be Defined with Short Synthetic Peptides. Cell 1986; 44: 959–968
   PubMed Web of Science ®Google Scholar
• Maryanski J.L., Paola P., Coradin G., Jordan B.R., Cerottini J.C. H-2 Restricted Cytotoxic T Cells Specific for HLA can Recognize a Synthetic HLA Peptide. Nature 1986; 324: 578–579
   PubMed Web of Science ®Google Scholar
• Clark W.H., Elder D.E., Guerry D.E., , et al. A Model Predicting Survival in Stage I Melanoma Based on Tumor Progression. J. Natl Cancer Inst. 1989; 81: 1893–1898
   PubMed Web of Science ®Google Scholar
• Paladugu R.R., Yonemoto R.H. Biologic Behavior of Thin Melanomas with Regressive Changes. Arch. Surg. 1983; 118: 41–45
   PubMed Web of Science ®Google Scholar
• Bystryn J.C., Rigel D., Friedman R.J., Kopf A. Prognostic Signficance of Hypopigmentation in Malignant Melanoma. Arch. Dermatol. 1987; 123: 1053–1055
   PubMed Web of Science ®Google Scholar
• Richards J.M., Mehta M., Schroeder L., , et al. Sequential Chemoimmunotherapy for Metastatic Melanoma. J. Clin. Oncol. 1992; 9: 1152–1160
   Google Scholar
• Nordlund J.J., Kirkwood J.M., Forget B.M., , et al. Vitiligo in Patients with Metastatic Melanoma: A Good Prognostic Sign. J. Am. Acad. Dermatol. 1983; 9: 689–697
   PubMed Web of Science ®Google Scholar
• Anichini A., Mazzocchi A., Fossatti G., Parmiani G. Cytotoxic Lymphocyte Clones from Peripheral Blood and from Tumor Sites Detect Intra-Tumoral Heterogeneity of Melanoma Cells: Analysis of Specificity and Mechanisms of Interaction. J. Immunol. 1989; 142: 3692–3701
   PubMed Web of Science ®Google Scholar
• Wolfel T., Klehmann E., Muller C., , et al. Lysis of Human Melanoma Cells by Autologous Cytolyitc T Cell Clones. Identification of Human Histocompatibility Leucocyte Antigen A2 as a Restriction Element for Three Different Antigens. J. Exp. Med. 1989; 170: 797–805
   PubMed Web of Science ®Google Scholar
• Topalian S.L., Solomon D., Rosenberg S.A. Tumor Specific Cytolysis by Lymphocytes Infiltrating Human Tumors. J. Immunol. 1989; 142: 3714–3725
   PubMed Web of Science ®Google Scholar
• Van Der Bruggen P., Traversari C., Chomez P., , et al. A Gene Encoding an Antigen Recognized by Cytolytic T Lymphocytes on a Human Melanoma. Science 1991; 254: 1643–1647
   PubMed Web of Science ®Google Scholar
• Traversari C., van der Bruggen P., Luescher I., , et al. A Nonapeptide Encoded by Human Gene MAGE-1 is Recognized on HLA-A1 by Cytolytic T Lymphocytes Directed Against Tumor Antigen MZ2-E. J. Exp. Med. 1992; 176: 1453–1457
   PubMed Web of Science ®Google Scholar
• Gauler B., van den Eynde B., van der Bruggen P., , et al. Human Gene MAGE-3 Codes for an Antigen Recognized on Melanoma Cells by Autologous Lymphocytes. J. Exp. Med. 1994; 179: 921–929
   PubMed Web of Science ®Google Scholar
• Kawakami Y., Eliyahu S., Delgado C., , et al. Cloning of the Gene Coding for a Shared Melanoma Antigen Recognized by Autologous T Cells Infiltrating into Tumor. Proc. Natl Acad. Sci. USA 1994; 96: 3515–3519
   Google Scholar
• Coulie P.G., Brichard V., Van Pel A., , et al. A New Gene Coding for a Differentition Antigen Recognized by Autologous Cytolytic T Lymphocytes on HLA-A2 Melanomas. J. Exp. Med. 1994; 180: 35–42
   PubMed Web of Science ®Google Scholar
• Kawakami Y., Eliyahu S., Sakaguchi K., , et al. Identification of the Immunodominant Peptides of the MART-1 Human Melanoma Antigen Recognized by the Majority of HLA-A2-Restricted Tumor Infiltrating Lymphocytes. J. Exp. Med. 1994; 180: 347–352
   PubMed Web of Science ®Google Scholar
• Stevens E., Jacknin L., Robbins P.F., , et al. The Generation of Tumor Specific Cytotoxic Lymphocytes from Melanoma Patients Using Peripheral Blood Stimulated with Allogeneic Melanoma Tumor Cell Lines: Fine Specificity and MART-1 Melanoma Antigen Recognition. J. Immunol. 1995; 154: 762–767
   PubMed Web of Science ®Google Scholar
• Romero P., Gervois N., Schneider J., Escobar P., Valmori D., Pannetier C., Steinle A., Wolfel T., Lienard D., Brichard V., Van Pel A., Jotereau F., Cerottini J.C. Cytolytic T Lymphocyte Recognition of the Immunodominant HLA-A*0201-Restricted Melan-A/MART-1 Antigenic Peptide in Melanoma. J. Immunol. 1997; 159: 2366–2374
   PubMed Web of Science ®Google Scholar
• Rivoltini L., Kawakami Y., Sakaguchi K., , et al. Induction of Tumor Reactive CTL from Peripheral Blood and Tumor-Infiltrating Lymphocytes of Melanoma Patients by In vitro Stimulation with an Immunodominant Peptide of the Human Melanoma Antigen MART-1. J. Immunol. 1995; 154: 2257–2265
   PubMed Web of Science ®Google Scholar
• Cole D.J., Weil D.P., Shilyansky J., , et al. Characterization of the Functional Specificity of a Cloned T-Cell Receptor Heterodimer Recognizing the MART-1 Melanoma Tumor Antigen. Cancer Res. 1995; 55: 748–752
   PubMed Web of Science ®Google Scholar
• Sensi M., Salvi S., Castelli C., , et al. T Cell Receptor Structure of Autologous Melanoma Reactive Cytotoxic T Lymphocyte (CTL) Clones: Tumor Infilrating Lymphocytes Overexpress In Vivo the TCR β Chain Sequence used by an HLA-A2 Restricted and Melanocyte Lineage-Specific CTL clone. J. Exp. Med. 1993; 178: 1231–1248
   PubMed Web of Science ®Google Scholar
• Hunt D.F., Henderson R.A., Shabanowitz J., , et al. Chracterization of Peptides Bound to the Class I Molecule HLA-A2.1 by Mass Spectrometry. Science 1992; 255: 1261–1264
   PubMed Web of Science ®Google Scholar
• Storkus W.J., Zeh H.J., Maeurer M.J., , et al. Identification of Human Melanoma Peptides Recognized by Class I Restricted Tumor Infiltrating Lymphocytes. J. Immunol. 1993; 151: 3719–3726
   PubMed Web of Science ®Google Scholar
• Cox A.L., Skipper J., Chen Y., , et al. Identification of a Peptide Recognized by Five Melanoma-Specific Human Cytotoxic T Cell Lines. Science 1994; 264: 716–719
   PubMed Web of Science ®Google Scholar
• Loftus D.J., Castelli C., Clay T.M., Squarcina P., Marincola F.M., Nishimura M.I., Parmiani G., Appella E., Rivoltini L. Identification of Epitope Mimics Recognized by CTL Reactive to the Melanoma/Melanocyte-Derived Peptide MART-1(27–35). J. Exp. Med. 1996; 184: 647–657
   PubMed Web of Science ®Google Scholar
• Marincola F.M., Rivoltini L., Salgaller M.L., Player M., Rosenberg S.A. Differential Anti-MART-1/MelanA CTL Activity in Peripheral Blood of HLA-A2 Melanoma Patients in Comparison to Healthy Donors: Evidence of In Vivo Priming by Tumor Cells. J. Immunother. 1996; 19: 266–277
   Web of Science ®Google Scholar
• Romero P., Dunbar P.R., Valmori D., Pittet M., , et al. Ex Vivo Staining of Metastatic Lymph Nodes by Class I Major Histocompatibility Complex Tetramers Reveals High Numbers of Antigen-Experienced Tumor Specific Cytolytic T Lymphocytes. J. Exp. Med. 1998; 188: 1641–1650
   PubMed Web of Science ®Google Scholar
• Fleischhauer K., Tanzarella S., Wallny H.J., Bordignon C., Traversari C. Multiple HLA-A Alleles can Present an Immunodominant Peptide of the Human Melanoma Antigen Melan-A/MART-1 to a Peptide-Specific HLA-A*0201+Cytotoxic T Cell Line. J. Immunol. 1996; 157: 787–797
   PubMed Web of Science ®Google Scholar
• Rivoltini L., Loftus D.J., Barracchini K., Arienti F., Mazzocchi A., Biddison W.E., Salgaller M.L., Appella E., Parmiani G., Marincola F.M. Binding and Presentation of Peptides Derived from Melanoma Antigens MART-1 and Glycoprotein-100 by HLA-A2 Subtypes. Implications for Peptide-Based Immunotherapy. J. Immunol. 1996; 156: 3882–3891
   PubMed Web of Science ®Google Scholar
• Schneider J., Brichard V., Boon T., Meyer zum Buschenfelde K.H., Wolfel T. Overlapping Peptides of Melanocyte Differentiation Antigen Melan-A/MART-1 Recognized by Autologous Cytolytic T Lymphocytes in Association with HLA-B45.1 and HLA-A2.1. Int. J. Cancer 1998; 75: 451–458
   PubMed Web of Science ®Google Scholar
• Marincola F.M. Stringent Allele/Epitope Requirements for MART-1/Melan-A Immunodominance: Implications for Peptide-Based Immunotherapy. J. Immunol. 1998; 161: 877–889
   PubMed Web of Science ®Google Scholar
• Jimenez M., Maloy W.L., Hearing V.J. Specific Identification of an Authentic Clone for Mammalian Tyrosinase. J. Biol. Chem. 1989; 264: 3397–3403
   PubMed Web of Science ®Google Scholar
• Adema G.J., DeBoer A.J., Vogel A.M., , et al. Molecular Characterization of the Melanocyte Lineage Specific Antigen gp100. J. Biol. Chem. 1994; 269: 20126–20133
   PubMed Web of Science ®Google Scholar
• Bakker A.B.H., Schreurs W.J., de Boer A.J., , et al. Melanocyte Lineage Specific Antigen gp100 is Recognized by Melanoma-Derived Tumor-Infiltrating Lymphocytes. J. Exp. Med. 1994; 179: 1005–1011
   PubMed Web of Science ®Google Scholar
• Kawakami Y., Eliyahu S., Delgado C., , et al. Identification of a Human Melanoma Antigen Recognized by Tumor-Infiltrating Lymphocytes Associated with In Vivo Tumor Rejection. Proc. Natl Acad. Sci. USA 1994; 91: 6458–6462
   PubMed Web of Science ®Google Scholar
• Bakker A.B.H., Schreurs M.W.J., Tafazzul G., , et al. Identification of a Novel Peptide Derived from the Melanocyte Specific gp100 Antigen as the Dominant Epitope Recognized by an HLA-A2.1 Restricted Anti-Melanoma CTL line. Int. J. Cancer 1995; 62: 97–102
   PubMed Web of Science ®Google Scholar
• Skipper J.C., Kittlesen D.J., Hendrickson R.C., Deacon D.D., , et al. Shared Epitopes for HLA-A3 Restricted Melanoma-Reactive Human Cytolytic T Lymphocytes Include a Naturally Processed Epitope from pMel17/gp100. J. Immunol. 1996; 157: 5027–5033
   PubMedGoogle Scholar
• Kawashima I., Tsai V., Southwood S., Takesako K., , et al. Idenitification of gp100-Derived Melanoma-Specific Cytolytic T Lymphocyte Epitopes Restricted by HLA-A3 Supertype Molecules by Primary In Vitro Immunization with Peptide-Pulsed Dendritic Cells. Int. J. Cancer 1998; 78: 518–524
   PubMed Web of Science ®Google Scholar
• Brichard V., Van Pel A., Wolfel T., , et al. The Tyrosinase Gene Encodes for an Antigen Recognized by Autologous Cytolytic T Lymphocytes on HLA-A2 Melanomas. J. Exp. Med. 1993; 178: 489–495
   PubMed Web of Science ®Google Scholar
• Wolfel T., Van Pel A., Brichard V., , et al. Two Tyrosinase Nonapeptides Recognized on HLA-A2 Melanomas by Autologous Cytolytic T Lymphocytes. Eur. J. Immunol. 1994; 24: 759–764
   PubMed Web of Science ®Google Scholar
• Skipper J.C.A., Hendrickson R.C., Gulden P.H., , et al. An HLA-A2 Restricted Tyrosinase Antigen on Melanoma Cells Results from Post-translational Modification and Suggests a Novel Processing Pathway for Membrane Proteins. J. Exp. Med. 1996; 183: 527–534
   PubMed Web of Science ®Google Scholar
• Wang R.F., Robbins P.F., Kawakami Y., , et al. Identification of a Gene Encoding a Melanoma Tumor Antigen Recognized by HLA-A31 Restricted Tumor-Infiltrating Lymphocytes. J. Exp. Med. 1995; 181: 799–806
   PubMed Web of Science ®Google Scholar
• Wang R.-F., Parkhurst M.R., Kawakami Y., Robbins P.F., , et al. Utilization of an Alternative Open Reading Frame of a Normal Gene in Generating a Human Cancer Antigen. J. Exp. Med. 1996; 183: 1131–1138
   PubMed Web of Science ®Google Scholar
• Wang R.-F., Appella E., Kawakami Y., Kang X., , et al. Identification of TRP-2 as a Human Tumor Antigen Recognized by Cytotoxic T Lymphocytes. J. Exp. Med. 1996; 184: 2207–2214
   PubMed Web of Science ®Google Scholar
• Jaeger E., Chen Y.-T., Drijfhout J.W., Karbach J., , et al. Simulataneous Humoral and Cellular Immune Response Against Cancer Testis Antigen NY-ESO-1: Definition of Human Histocompatibility Leucocyte Antigen (HLA)-A2 Binding Peptide Epitopes. J. Exp. Med. 1998; 187: 265–274
   PubMedGoogle Scholar
• Wang R.-F., Johnston S.L., Zeng G., Topalian S.L., , et al. A Breast and Melanoma-Shared Tumor Antigen: T Cell Responses to Antigenic Peptides Translated from Different Open Reading Frames. J. Immunol. 1998; 161: 3596–3606
   Web of Science ®Google Scholar
• Wolfel T., Hauer M., Schneider J., Serrano M., , et al. A p16INK4a-Insensitive CDK4 Mutant Targeted by Cytotoxic T Lymphocytes in a Human Melanoma. Science 1995; 269: 1281–1285
   PubMed Web of Science ®Google Scholar
• Robbins P.F., El-Gamil M., Li Y.F., Kawakami Y., , et al. A Mutated Beta-Catenin Gene Encodes a Melanoma Specific Antigen Recognized by Tumor-Infiltrating Lymphocytes. J. Exp. Med. 1996; 183: 1185–1192
   PubMed Web of Science ®Google Scholar
• Coulie P.G., Lehmann F., Lethe B., Herman J., , et al. A Mutated Intron Sequence Codes for an Antigenic Peptide Recognized by Cytolytic T Lymphocytes on a Human Melanoma. Proc. Natl Acad. Sci. USA 1995; 92: 7976–7980
   PubMed Web of Science ®Google Scholar
• Fu Y.S., Huang I., Beaudenon S., , et al. Correlative Study of HPV, DNA, Histopathology and Morphometry in Cervical Condyloma and Intraepithelial Neoplasia. Int. J. Gynecol. Pathol. 1988; 7: 297–303
   PubMed Web of Science ®Google Scholar
• Crook T., Morgenstern J.P., Crawford L., Banks L. Continuous Expression of the HPV E7 Protein is Required for the Maintenance of the Transformed Phenotype of Cells Co-Transformed by HPV 16 Plus EJ-ras. EMBO J. 1989; 8: 513–519
   PubMed Web of Science ®Google Scholar
• Munger K., Scheffner M., Huibregste J.M., Howley P.M. Interactions of HPV E6 and E7 Proteins with Tumor Suppressor Gene Products. Cancer Surv. 1992; 12: 197–217
   PubMedGoogle Scholar
• Ressing M.E., Sette A., Brandt R., Ruppert J., , et al. Human CTL Epitopes Encoded by Human Papillomavirus Type 16 E6 and E7 Identified Through In Vivo and In Vitro Immunogenicity Studies of HLA-A0201 Binding Peptides. J. Immunol. 1995; 154: 5934–5943
   PubMed Web of Science ®Google Scholar
• Alexander M., Salgaller M.L., Celis E., Sette A., , et al. Generation of Tumor-Specific CTL from the Peripheral Blood of Cervical Cancer Patients by In Vitro Stimulation with a Synthetic HPV-16 E7 Epitope. Am. J. Obstet. Gynnecol. 1996; 175: 1586–1593
   PubMed Web of Science ®Google Scholar
• Steller M.A., Gursk K.J., Murakami M., Daniel R.W., , et al. Cell Mediated Immunologic Responses in Cervical and Vaginal Cancer Patients Immunized with a Lipidated Epitope of Human Papillomavirus Type 16 E7. Clin. Cancer Res. 1998; 4: 2103–2109
   PubMed Web of Science ®Google Scholar
• Van Driel W.J., Ressing K.E., Kenter C.G., Brandt R.M., , et al. Vaccination of HPV 16 Peptides of Patients with Advanced Cervical Carcinoma: Clinical Evaluation of a Phase I/II trial. Eur. J. Cancer 1999; 35(6)946–952
   PubMed Web of Science ®Google Scholar
• Zaks T.Z., Rosenberg S.A. Immunization with a Peptide Vaccine (p369–377) from HER2/neu Leads to Peptide-Specific Cytotoxic T Lymphocytes that Fail to Recognize HER-2/neu Positive Tumors. Cancer Res. 1998; 58(21)4902–4908
   PubMed Web of Science ®Google Scholar
• Disis M.L., Grabstein K.H., Sleath P.R., Cheever M.A., , et al. Generation of Immunity to the HER2/neu Oncogenic Protein in Patients with Breast and Ovarian Cancer Using a Peptide-Based Vaccine. Clin. Cancer Res. 1999; 5(6)1289–1297
   PubMed Web of Science ®Google Scholar
• Khleif S.N., Abrams S.I., Hamilton J.M., Bergmann-Leitner E., , et al. A Phase I Vaccine Trial with Peptides Reflecting ras Oncogene Mutations of Solid Tumors. J. Immunother. 1999; 22(2)155–165
   PubMed Web of Science ®Google Scholar
• Gjertsen M.K., Bjorheim J., Seaterdal I., Myklebust J., Gaudernack G. Cytotoxic CD4+ and CD8+ T Lymphocytes Generated by Mutant p21 ras (12Val) Peptide Vaccination of a Patient Recognize 12Val-Dependent Nested Epitopes Present Within the Vaccine Peptide and Kill Autologous Tumor Cells Carrying the Mutation. Int. J. Cancer 1997; 72(5)784–790
   PubMed Web of Science ®Google Scholar
• Osman Y., Takahashi M., Zheng Z., Toba K., , et al. Generation of bcr–abl Specific Cytotoxic T-Lymphocytes by Using Dendritic Cells Pulsed with the bcr–abl (b3a2) Peptide: its Applicability for Donor Leucocyte Transfusion in Marrow Grafted CML. Leukemia 1999; 13(2)166–174
   PubMed Web of Science ®Google Scholar
• Scheinberg D.A., Cathcart K.N., Korontsvit T.A., Pinilla J., , et al. bcr–abl Breakpoint Derived Oncogene Fusion Peptide Vaccines Generate Specific Immune Responses in Patients with Chronic Myelogenous Leukemia (CML). Proc. Am. Soc. Clin. Oncol. 1999; 18(432a)
   Google Scholar
• Marchand M., , et al. Tumor Regression Responses in Melanoma Patients Treated with a Peptide Encoded by MAGE-3. Int. J. Cancer 1995; 63: 883–885
   PubMed Web of Science ®Google Scholar
• Weber J.S., Hua F.L, Spears L., Marty V. A Phase I Trial of a HLA-A1 Restricted MAGE-3 Epitope Peptide with Incomplete Freund's Adjuvant in Patients with Resected High-Risk Melanoma. J. Immunother. 1999; 1999
   Google Scholar
• Marchand M., van Baren N., Weynants P., Brichard V., , et al. Tumor Regressions Observed in Patients with Metastatic Melanoma Treated with an Antigenic Peptide Encoded by Gene MAGE-3 and Presented by HLA-A1. Int. J. Cancer 1999; 80: 219–230
   PubMed Web of Science ®Google Scholar
• Jaeger E., Bernhard H., Romero P., Ringhoffer M., , et al. Generation of Cytotoxic T Cell Responses with Synthetic Melanoma-Associated Peptide In Vivo: Implications for Tumor Vaccines with Melanoma-Associated Antigens. Int. J. Cancer 1996; 66: 162–170
   PubMed Web of Science ®Google Scholar
• Jaeger E., Ringhoffer M., Dienes H.-P., Arand M., , et al. Granulocyte Macrophage Colony Stimulating Factor Enhances Immune Responses to Melanoma Associated Peptides In Vivo. Int. J. Cancer 1997; 67: 54–62
   Web of Science ®Google Scholar
• Jaeger E., Ringhoofer M., Karbac J., , et al. Inverse Relationship of Melanoma Differentiation Antigen Expression in Melanoma Tissues and CD8+ Cytotoxic T Cell Responses: Evidence for Immunoselection of Antigen Loss Variants In Vivo. Int. J. Cancer 1996; 66: 470–476
   PubMed Web of Science ®Google Scholar
• Cebon J.S., Jaeger E., Gibbs P., Davis I., Hopkins W., Gibbs S., Chen Q., Karlbach J., Jackson H., MacGregor D., Sturrock D., Marakovsky E., Sherman M., Knuth A. Phase I Studies of Immunization with Melan-A and IL-12 in HLA-A2 Positive Patients with Stage III and IV Metastatic Melanoma. Proc. Am. Soc. Clin. Oncol. 1999; 18(434a)
   Google Scholar
• Scheibenbogen C., Schmittel A., Keiholz U., Allgauer T., Hofmann U., Thiel E., Schadendorf D. Vaccination with Tyrosinase Peptides and GM-CSF in Metastatic Melanoma. Proc. Am. Soc. Clin. Oncol. 1999; 18(436a)
   Google Scholar
• Salgaller M.L., Marincola F.M., Cormier J.N., , et al. Immunization Against Epitopes in the Human Melanoma Antigen gp100 Following Patient Immunization with Synthetic Peptides. Cancer Res. 1996; 56: 4749–4757
   PubMed Web of Science ®Google Scholar
• Salgaller M.L., Afshar A., Marincola F.M., , et al. Recognition of Multiple Epitopes of the Human Melanoma Antigen gp100 by Peripheral Blood Lymphocytes Stimulated In Vitro with Synthetic Peptides. Cancer Res. 1995; 55: 4972–4977
   PubMed Web of Science ®Google Scholar
• Cormier J.N., Salgaller M.L., Prevette T., Barracchini K.C., Rivoltini L., Restifo N.P., Rosenberg S.A., Marincola F.M. Enhancement of Cellular Immunity in Melanoma Patients Immunized with a Peptide from MART-1/Melan A. Cancer J. Sci. Am. 1997; 3: 37–44
   PubMed Web of Science ®Google Scholar
• Parkhurst M.R., Salgaller M.L., Southwood S., Robbins P.F., , et al. Improved Induction of Melanoma Reactive CTL with Peptides from Melanoma Antigen gp100 Modified at HLA-A0201 Binding Residues. J. Immunol. 1996; 157: 2536–2548
   Google Scholar
• Wang F., Bade E., Kuniyoshi C., Spear L., , et al. Phase I Trial of a MART-1 Peptide Vaccine with Incomplete Freund's Adjuvant for Resected High-Risk Melanoma. Clin. Cancer Res. 1999; 5(10)2756–2765
   PubMed Web of Science ®Google Scholar
• Valmori D., Fonteneau J.F., Lizana C.M., Gervois N., Lienard D., Rimoldi D., Jongeneel V., Jotereau F., Cerottini J.C., Romero P. Enhanced Generation of Specific Tumor-Reactive CTL In Vitro by Selected Melan-A/MART-1 Immunodominant Peptide Analogues. J. Immunol. 1998; 160: 1750–1758
   PubMed Web of Science ®Google Scholar
• Rosenberg S.A., Yang J.C., Schwartzentruber D.J., Hwu P., , et al. Immunologic and Therapeutic Evaluation of a Synthetic Peptide Vaccine for the Treatment of Patients with Metastatic Melanoma. Nat. Med. 1998; 4: 321–327
   PubMed Web of Science ®Google Scholar
• Rosenberg S.A., Lotze M.T., Yang J.C., Parkinson D.R., , et al. Experience with the Use of High-Dose Interleukin-2 in the Treatment of 652 Cancer Patients. Ann. Surg. 1990; 210: 474–480
   Web of Science ®Google Scholar
• Parkinson D.R., Abrams J.S., Wiernik P.H., , et al. Interleukin-2 Therapy in Patients with Metastatic Melanoma: A Phase II study. J. Clin. Oncol. 1990; 8: 1650–1659
   PubMed Web of Science ®Google Scholar
• Rosenberg S.A., Yang J.C., Schwartzentruber D.J., Hwu P., , et al. Impact of Cytokine Administration on the Generation of Anti-Tumor Reactivity in Patients with Metastatic Melanoma Receiving a Peptide Vaccine. J. Immunol. 1999; 163(3)1690–1695
   PubMed Web of Science ®Google Scholar
• Lewis J.J., Janetski S., Wang S., Williams S. Phase I Trial of Vaccination with Tyrosinase Peptide Plus QS-21 in Melanoma. Proc. Am. Soc. Clin. Oncol. 1998; 17(428a)1650
   Google Scholar
• Mukherji B., Chakraborty N.G., Yamasaki S., Okino T., , et al. Induction of Antigen-Specific Cytolytic T Cells In Situ in Human Melanoma by Immunization with Synthetic Peptide-Pulsed Autologous Antigen Presenting Cells. Proc. Natl Acad. Sci. USA 1995; 92: 8079–8082
   Google Scholar
• Fallarino F., Uyttenhove C., Boon T., Gajewski T.F. Improved Efficacy of Dendritic Cell Vaccines and Successful Immunization with Tumor Antigen Peptide-Pulsed Peripheral Blood Mononuclear Cells by Coadministration of Recombinant Murine Interleukin-12. Int. J. Cancer 1999; 80(2)324–333
   PubMed Web of Science ®Google Scholar
• Chen Y.T., Stockert E., Jungbluth A., Tsang S., Coplan K.A., Scanlan M.J., Old L.J. Serological Analysis of Melan-A (MART-1), a Melanocyte-Specific Protein Homogeneously Expressed in Human Melanomas. Proc. Natl Acad. Sci. USA 1996; 93: 5915–5919
   PubMed Web of Science ®Google Scholar
• Marincola F.M., Hijazi Y.M., Fetsch P., Salgaller M.L., Rivoltini L., Cormier J., Simonis T.B., Duray P.H., Herlyn M., Kawakami Y., Rosenberg S.A. Analysis of Expression of the Melanoma-Associated Antigens MART-1 and gp100 in Metastatic Melanoma Cell Lines and in In Situ Lesions. J. Immunother. 1996; 19: 192–205
   PubMed Web of Science ®Google Scholar
• Taylor-Papadimitriou J., Finn O.J. Biology, Biochemistry and Immunology of Carcinoma Associated Mucins. Immunol. Today 1997; 18(3)105–107
   PubMedGoogle Scholar
• Goydos J.S., Elder E., Whiteside T.L., Finn O.J., Lotze M.T. A Phase I Trial of a Synthetic Mucin Peptide Vaccine: Induction of Specific Immune Reactivity in Patients with Adenocarcinoma. J. Surg. Res. 1996; 63(1)298–304
   PubMed Web of Science ®Google Scholar
• Brossart P., Heinrich K.S., Stuhler G., Behnke L., , et al. Identification of HLA-A2 Restricted T-Cell Epitopes Derived from the MUC1 Tumor Antigen for Broadly Applicable Vaccine Therapies. Blood 1999; 93(12)4309–4317
   PubMed Web of Science ®Google Scholar
• Jerome K.R., Kirk A.D., Pecher G., Ferguson W.W., Finn O.J. A Survivor of Breast Cancer with Immunity to MUC-1 Mucin, and Lactational Mastitis. Cancer Immunol. Immunother. 1997; 43(6)355–360
   PubMed Web of Science ®Google Scholar
• Kageshita T., Kawakami Y., Hirai S., Ono T. Differential Expression of MART-1 in Primary and Metastatic Melanoma Lesions. J. Immunother. 1997; 20: 460–465
   PubMed Web of Science ®Google Scholar
• Fetsch P.A., Cormier J., Hijazi Y.M. Immunocytochemical Detection of MART-1 in Fresh and Paraffin-Embedded Malignant Melanomas. J. Immunother. 1997; 20: 60–64
   PubMed Web of Science ®Google Scholar
• de Vries T.J., Fourkour A., Wobbes T., Verkroost G., Ruiter D.J., van Muijen G.N. Heterogeneous Expression of Immunotherapy Candidate Proteins gp100 MART-1, and Tyrosinase in Human Melanoma Cell Lines and in Human Melanocytic Lesions. Cancer Res. 1997; 57: 3223–3229
   PubMed Web of Science ®Google Scholar
• Dalerba P., Ricci A., Russo V., Rigatti D., Nicotra M.R., Mottolese M., Bordignon C., Natali P.G., Traversari C. High Homogeneity of MAGE, BAGE, GAGE, Tyrosinase and Melan-A/MART-1 Gene Expression in Clusters of Multiple Simultaneous Metastases of Human Melanoma: Implications for Protocol Design of Therapeutic Antigen-Specific Vaccination Strategies. Int. J. Cancer 1998; 77: 200–204
   PubMed Web of Science ®Google Scholar
• Cormier J.N., Abati A., Fetsch P., Hijazi Y.M., Rosenberg S.A., Marincola F.M., Topalian S.L. Comparative Analysis of the In Vivo Expression of Tyrosinase MART-1/Melan-A, and gp100 in Metastatic Melanoma Lesions: Implications for Immunotherapy. J. Immunother. 1998; 21: 27–31
   PubMed Web of Science ®Google Scholar
• Maeurer M.J., Gollin S.M., Martin D., Swaney W., Bryant J., Castelli C., Robbins P., Parmiani G., Storkus W.J., Lotze M.T. Tumor Escape from Immune Recognition: Lethal Recurrent Melanoma in a Patient Associated with Downregulation of the Peptide Transporter Protein TAP-1 and Loss of Expression of the Immunodominant MART-1/Melan-A Antigen. J. Clin. Invest. 1996; 98: 1633–1641
   PubMed Web of Science ®Google Scholar
• Pittet M.J., Valmori D., Dunbar P.R., Speiser D.E., , et al. High Frequencies of Naïve Melan A/MART-1-Specific CD8+ T Cells in a Large Proportion of Human Histocompatibility Leucocyte Antigen (HLA)-A2 Individuals. J. Exp. Med. 1999; 190: 705–715
   PubMed Web of Science ®Google Scholar
• Lee P.P., Yee C., Savage P.A., Fong L., , et al. Characterization of Circulating T Cells Specific for Tumor-Associated Antigens in Melanoma Patients. Nat. Med. 1999; 5: 677–685
   PubMed Web of Science ®Google Scholar
• Finke J.H., Zea A.H., Stanley J., Longo D.L., , et al. Loss of T-Cell Receptor ζ-Chain and p56lck in T-Cells Infiltrating Human Carcinomas. Cancer Res. 1993; 53: 5613–5618
   PubMed Web of Science ®Google Scholar
• Nakagomi H., Petersson M., Magnusson I., Juhlin C., , et al. Decreased Expression of the Signal-Transducing ζ Chains in Tumor Infiltrating Cells and NK Cells of Patients with Colorectal Carcinoma. Cancer Res. 1993; 53: 5610–5612
   PubMed Web of Science ®Google Scholar
• Zea A.H., Brendan C.D., Longo D.L., Alvord W.G., , et al. Alterations in T Cell Receptor and Signal Transduction Molecules in Melanoma Patients. Clin. Cancer Res. 1995; 1: 1327–1335
   PubMed Web of Science ®Google Scholar